CN112220714A - Red ginseng vigor activating oxygen eye cream and preparation method thereof - Google Patents
Red ginseng vigor activating oxygen eye cream and preparation method thereof Download PDFInfo
- Publication number
- CN112220714A CN112220714A CN202010954426.6A CN202010954426A CN112220714A CN 112220714 A CN112220714 A CN 112220714A CN 202010954426 A CN202010954426 A CN 202010954426A CN 112220714 A CN112220714 A CN 112220714A
- Authority
- CN
- China
- Prior art keywords
- phase
- solution
- red ginseng
- eye cream
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 39
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 32
- 230000003213 activating effect Effects 0.000 title claims abstract description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 239000001301 oxygen Substances 0.000 title claims abstract description 21
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920001577 copolymer Polymers 0.000 claims abstract description 7
- -1 glyceryl glucoside Chemical class 0.000 claims abstract description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 4
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 claims abstract description 4
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims abstract description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 4
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 4
- 108010087806 Carnosine Proteins 0.000 claims abstract description 4
- 244000298479 Cichorium intybus Species 0.000 claims abstract description 4
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 4
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000043 antiallergic agent Substances 0.000 claims abstract description 4
- 229940044199 carnosine Drugs 0.000 claims abstract description 4
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 4
- 229960003993 chlorphenesin Drugs 0.000 claims abstract description 4
- 229930182478 glucoside Natural products 0.000 claims abstract description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims abstract description 4
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 4
- 150000004702 methyl esters Chemical class 0.000 claims abstract description 4
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 4
- 229940078492 ppg-17 Drugs 0.000 claims abstract description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims abstract 3
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 238000003756 stirring Methods 0.000 claims description 50
- 239000002994 raw material Substances 0.000 claims description 46
- 238000001514 detection method Methods 0.000 claims description 32
- 230000001804 emulsifying effect Effects 0.000 claims description 25
- 238000001816 cooling Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 15
- 239000003995 emulsifying agent Substances 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 10
- 229920002545 silicone oil Polymers 0.000 claims description 10
- 235000013871 bee wax Nutrition 0.000 claims description 7
- 239000012166 beeswax Substances 0.000 claims description 7
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 6
- 238000007599 discharging Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 235000019198 oils Nutrition 0.000 claims description 5
- 238000005086 pumping Methods 0.000 claims description 5
- 238000005070 sampling Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 claims description 3
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000018330 Macadamia integrifolia Nutrition 0.000 claims description 3
- 240000000912 Macadamia tetraphylla Species 0.000 claims description 3
- 235000003800 Macadamia tetraphylla Nutrition 0.000 claims description 3
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 3
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000010466 nut oil Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- 229940047670 sodium acrylate Drugs 0.000 claims description 3
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- 235000011187 glycerol Nutrition 0.000 claims 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- NLZCOTZRUWYPTP-MIUGBVLSSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLZCOTZRUWYPTP-MIUGBVLSSA-N 0.000 claims 1
- NLZCOTZRUWYPTP-UHFFFAOYSA-N acacetin-7-O-beta-D-galactoside Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2OC1C(O)C(O)C(O)C(CO)O1 NLZCOTZRUWYPTP-UHFFFAOYSA-N 0.000 claims 1
- GWOKWCRSUJQOMD-UHFFFAOYSA-N tilianin Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=CC=C2OC1C(O)C(O)C(O)C(CO)O1 GWOKWCRSUJQOMD-UHFFFAOYSA-N 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 abstract description 6
- 235000002673 Dioscorea communis Nutrition 0.000 abstract description 5
- 241000544230 Dioscorea communis Species 0.000 abstract description 5
- 208000035753 Periorbital contusion Diseases 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 8
- 230000037394 skin elasticity Effects 0.000 description 6
- 238000005562 fading Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses red ginseng vigor activating oxygen eye cream and a preparation method thereof, and the red ginseng vigor activating oxygen eye cream comprises water, methyl propylene glycol, glycerol, hyaluronic acid, EDTA disodium, methyl ester, glyceryl polyether-26, PEG/PPG-17/6 copolymer, red ginseng extract, carnosine, dipalmitoyl hydroxyproline, glyceryl glucoside, chicory tiramer, a compound anti-allergy agent, essence, phenoxyethanol/chlorphenesin and the like. The invention has excellent moisturizing performance, and can effectively fade fine lines and black eye circles.
Description
Technical Field
The invention relates to the field of eye cream production and preparation, and particularly relates to red ginseng vigor activating oxygen eye cream and a preparation method thereof.
Background
The eye cream is one of skin care cosmetics and has the function of moistening eye skin. The eye mask can reduce the problems of dark circles and under-eye bags, and also has the effect of improving wrinkles and fine lines. The eye cream is used for protecting the thin skin around the eyes, has certain effects on pouches, black eye circles, crow's feet and the like, but different eye creams have different effects and are divided into moisturizing eye cream, firming eye cream, anti-aging eye cream, anti-allergy eye cream and the like in terms of functions.
The existing eye cream has poor moisturizing performance, and has common effects of fading fine lines and fading black eye circles. It is still difficult to meet the requirements of people. In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The invention aims to design red ginseng original qi oxygen activating eye cream and a preparation method thereof, so that the red ginseng original qi oxygen activating eye cream has excellent moisturizing performance, and can effectively lighten fine lines and black eyes.
In order to achieve the purpose, the invention provides the following technical scheme:
red ginseng original qi oxygen activating eye cream is prepared from the following raw materials in percentage by weight:
phase A: water 31.05-68.43%, preferably 64.01%; 4-5%, preferably 4%; 2-5% of glycerol, preferably 2%; hyaluronic acid 0.01-0.05%, preferably 0.02%; disodium EDTA 0.01-0.05%, preferably 0.02%; methyl ester 0.1-0.2%, preferably 0.2%; glyceryl polyether-262-5%, preferably 3%; PEG/PPG-17/6 copolymer 0.5-3%, preferably 1%;
phase B: 2-4% of emulsifier A, preferably 2.5%; 0.5-1% of emulsifier B, preferably 0.5%; beeswax 0.5-1%, preferably 0.8%; GMS 30SE 0.5-1.5%, preferably 1.2%; 0.3-1% of 16\18 alcohol, preferably 0.4%; propyl ester 0.1-0.15%, preferably 0.1%; 0.5-1% of shea butter, preferably 0.5%; 0.5-1% of silicone oil A, preferably 0.5%; 0.5-1%, preferably 0.5%; 3-5%, preferably 3%; 2-5% of macadamia nut oil, preferably 2%; 2-5%, preferably 3%; 2-5% of silicone oil B, preferably 3%;
and C phase: sodium acrylate/sodium acryloyldimethyl taurate copolymer/isohexadecane/polysorbate-801-2%, preferably 1%;
phase D: 0.5-2%, preferably 0.6%; carnosine 0.2-0.5%, preferably 0.2%; dipalmitoyl hydroxyproline 1-3%, preferably 1%; 3-6% of water, preferably 3%;
phase E: 0.5-2% of glycerol glucoside, preferably 0.5%; chicory tiramer 0.5-2%, preferably 0.5%; 0.5-1% of composite anti-allergic agent, preferably 0.5%; 0.05 to 0.1 percent of essence, preferably 0.1 percent; 0.3 to 0.4 percent of phenoxyethanol/chlorphenesin, preferably 0.35 percent.
Further, silicone oil A in phase B is polydimethylsiloxane, silicone oil B is cyclopentadimethylsiloxane/cyclohexasiloxane, beeswax is beeswax 8044, emulsifier A is M68 emulsifier, and emulsifier B is A165 emulsifier.
Further, the water in the A phase and the D phase is deionized water.
The preparation method of the red ginseng vigor activating oxygen eye cream comprises the following steps:
step 1: proportioning raw materials of the phase A, the phase B, the phase C, the phase D and the phase E;
step 2: mixing, dispersing and stirring the phase D raw material uniformly to obtain a solution A;
step 2: putting the phase A raw material into a vacuum homogenizing emulsifying pot, starting stirring at the rotating speed of 60rpm, heating to 85-90 ℃, continuously stirring and preserving heat for 5-8min to obtain a solution B;
and step 3: putting the phase B raw material into an oil phase pot, starting stirring at the rotating speed of 40rpm, heating to 80-85 ℃, continuously stirring and preserving heat for 5-8min to completely dissolve the raw material to obtain a solution C;
and 4, step 4: opening the vacuum homogenizing emulsifying pot in the step 2 to be vacuum, starting stirring, rotating at the speed of 60rpm, pumping the solution C obtained in the step 3 into the vacuum homogenizing emulsifying pot, mixing the solution C with the solution B, opening the vacuum homogenizing emulsifying pot to be homogenized at the speed of 2800rpm, homogenizing for 5min, stirring at the speed of 30rpm, preserving heat, stirring for 8-10min, and then cooling to obtain a solution D;
and 5: cooling the solution D obtained in the step 4 to 60 ℃, adding the phase C raw material into a vacuum homogenizing emulsifying pot, mixing the phase C raw material with the solution D, starting homogenizing at the rotating speed of 2500rpm for 2min, and continuously stirring and cooling to obtain a solution E;
step 6: cooling the solution E obtained in the step 5 to 45 ℃, then adding the solution A and the E-phase raw material obtained in the step 1, and continuously stirring for 20-30min to obtain a solution F:
and 7: and (4) sampling and detecting the solution F obtained in the step (6), and filtering and discharging after the solution F is qualified.
Further, the detection in step 7 includes appearance detection, viscosity detection, pH value detection, heat resistance detection, cold resistance detection and centrifugation detection.
Compared with the prior art, the invention has the beneficial effects that:
the red ginseng is a cooked product of ginseng and has the effects of greatly tonifying primordial qi, recovering pulse, relieving depletion, benefiting qi and controlling blood. In clinic, the red ginseng extract can be applied to improve the related functions of the human body, particularly to regulate blood pressure, resist fatigue, calm the nerves, supplement the brain and the like. From the above-mentioned functions, the health value of red ginseng is very high. Because the red reference ginseng has larger potency of medicine, the warm and dry property is larger, and the dosage is a little less than that of the common ginseng.
In the eye cream production process, based on long-term continuous experimental data, the red ginseng extract is added in a reasonable amount, and the addition amounts of other raw materials are correspondingly and reasonably adjusted. The eye cream has excellent moisturizing performance, and can effectively fade fine lines and black eye circles.
Detailed Description
Examples 1 to 3:
red ginseng original qi oxygen activating eye cream of examples 1-3 was prepared according to the following raw materials in the following table 1 by weight percent, respectively.
Table 1:
wherein, the red ginseng original qi oxygen activating eye cream prepared in the following modes of example 1-3 respectively:
example 1:
step 1: proportioning raw materials of the phase A, the phase B, the phase C, the phase D and the phase E;
step 2: mixing, dispersing and stirring the phase D raw material uniformly to obtain a solution A;
step 2: putting the phase A raw material into a vacuum homogenizing emulsifying pot, starting stirring, rotating at the speed of 60rpm, heating to 85 ℃, continuously stirring and preserving heat for 5min to obtain a solution B;
and step 3: putting the phase B raw material into an oil phase pot, starting stirring, rotating at 40rpm, heating to 80 ℃, continuously stirring and preserving heat for 5min to completely dissolve the raw material to obtain a solution C;
and 4, step 4: opening the vacuum homogenizing emulsifying pot in the step 2 to vacuum, starting stirring at a rotating speed of 60rpm, pumping the solution C obtained in the step 3 into the vacuum homogenizing emulsifying pot, mixing the solution C with the solution B, opening the vacuum homogenizing emulsifying pot to homogenize at a rotating speed of 2800rpm for 5min, stirring at a rotating speed of 30rpm, preserving heat, stirring for 8min, and then cooling to obtain a solution D;
and 5: cooling the solution D obtained in the step 4 to 60 ℃, adding the phase C raw material into a vacuum homogenizing emulsifying pot, mixing the phase C raw material with the solution D, starting homogenizing at the rotating speed of 2500rpm for 2min, and continuously stirring and cooling to obtain a solution E;
step 6: cooling the solution E obtained in the step 5 to 45 ℃, then adding the solution A obtained in the step 1 and the phase E raw material, and continuously stirring for 20min to obtain a solution F:
and 7: and (4) sampling and detecting the solution F obtained in the step (6), and filtering and discharging after the solution F is qualified.
Example 2:
step 1: proportioning raw materials of the phase A, the phase B, the phase C, the phase D and the phase E;
step 2: mixing, dispersing and stirring the phase D raw material uniformly to obtain a solution A;
step 2: putting the phase A raw material into a vacuum homogenizing emulsifying pot, starting stirring, rotating at 60rpm, heating to 88 ℃, continuously stirring, and keeping the temperature for 5-8min to obtain a solution B;
and step 3: putting the phase B raw material into an oil phase pot, starting stirring, rotating speed of 40rpm, heating to 83 ℃, continuously stirring and keeping the temperature for 6min to completely dissolve the raw material to obtain a solution C;
and 4, step 4: opening the vacuum homogenizing emulsifying pot in the step 2 to vacuum, starting stirring at a rotating speed of 60rpm, pumping the solution C obtained in the step 3 into the vacuum homogenizing emulsifying pot, mixing the solution C with the solution B, opening the vacuum homogenizing emulsifying pot to homogenize at a rotating speed of 2800rpm for 5min, stirring at a rotating speed of 30rpm, preserving heat, stirring for 9min, and then cooling to obtain a solution D;
and 5: cooling the solution D obtained in the step 4 to 60 ℃, adding the phase C raw material into a vacuum homogenizing emulsifying pot, mixing the phase C raw material with the solution D, starting homogenizing at the rotating speed of 2500rpm for 2min, and continuously stirring and cooling to obtain a solution E;
step 6: cooling the solution E obtained in the step 5 to 45 ℃, then adding the solution A obtained in the step 1 and the phase E raw material, and continuously stirring for 25min to obtain a solution F:
and 7: and (4) sampling and detecting the solution F obtained in the step (6), and filtering and discharging after the solution F is qualified.
Example 3:
step 1: proportioning raw materials of the phase A, the phase B, the phase C, the phase D and the phase E;
step 2: mixing, dispersing and stirring the phase D raw material uniformly to obtain a solution A;
step 2: putting the phase A raw material into a vacuum homogenizing emulsifying pot, starting stirring, rotating at the speed of 60rpm, heating to 90 ℃, continuously stirring and preserving heat for 8min to obtain a solution B;
and step 3: putting the phase B raw material into an oil phase pot, starting stirring at the rotating speed of 40rpm, heating to 85 ℃, continuously stirring and preserving heat for 8min to completely dissolve the raw material to obtain a solution C;
and 4, step 4: opening the vacuum homogenizing emulsifying pot in the step 2 to vacuum, starting stirring at a rotating speed of 60rpm, pumping the solution C obtained in the step 3 into the vacuum homogenizing emulsifying pot, mixing the solution C with the solution B, opening the vacuum homogenizing emulsifying pot to homogenize at a rotating speed of 2800rpm for 5min, stirring at a rotating speed of 30rpm, keeping the temperature and stirring for 8-10min, and then, starting cooling to obtain a solution D;
and 5: cooling the solution D obtained in the step 4 to 60 ℃, adding the phase C raw material into a vacuum homogenizing emulsifying pot, mixing the phase C raw material with the solution D, starting homogenizing at the rotating speed of 2500rpm for 2min, and continuously stirring and cooling to obtain a solution E;
step 6: cooling the solution E obtained in the step 5 to 45 ℃, then adding the solution A and the E-phase raw material obtained in the step 1, and continuously stirring for 30min to obtain a solution F:
and 7: and (4) sampling and detecting the solution F obtained in the step (6), and filtering and discharging after the solution F is qualified.
Experimental example 1:
the red ginseng original qi activating oxygen eye cream products prepared in examples 1-3 were tested and compared. The detection items comprise appearance detection, viscosity detection, pH value detection, heat resistance detection, cold resistance detection and centrifugation detection. The detection results are shown in table 2:
wherein, the appearance detection detects whether the product appearance is white paste or not; detecting whether the viscosity of the product meets 60000 +/-1000 by viscosity detection; detecting whether the pH value of the product meets 7.2 +/-0.5 by pH value detection; the heat resistance detection detects that the product is put into a constant temperature box at 40 +/-1 ℃ for 24H, then is taken out and recovered to room temperature, and is compared with a standard sample to observe whether the material body is not obviously different; cold resistance detection is carried out to detect whether the product is placed in a refrigerator for 24H at minus 8 +/-2 ℃, then the product is taken out and recovered to room temperature, and the room temperature is compared with a standard sample, and whether the material body is not obviously different is observed; centrifugal test the product was spun in a centrifuge at 2000rpm for 30min and observed for lack of stratification.
TABLE 2
Detecting items | Example 1 | Example 2 | Example 3 |
Appearance detection | Qualified | Qualified | Qualified |
Viscosity detection | Qualified | Qualified | Qualified |
pH value detection | Qualified | Qualified | Qualified |
Heat resistance detection | Qualified | Qualified | Qualified |
Cold resistance detection | Qualified | Qualified | Qualified |
Centrifugal assay | Qualified | Qualified | Qualified |
As can be seen from Table 1, examples 1-3 all satisfied the test requirements, and it was confirmed that the formulation and the preparation method of the present invention both satisfied the product requirements.
Experimental example 2:
the red ginseng original oxygen-activating eye cream prepared in example 1 was subjected to a skin elasticity index test. The experimental conditions are as follows: 40 women, age 30-50 years old, volunteers. The experimental steps are as follows: the skin elasticity CotomerMPA 580 host manufactured by Courage + Khazaka, Germany, was used as a probe for a Reviscometer RV600 elasto-fibrous tissue test probe, and the average was taken five times. Test area: the skin around the eyes. Blank values (R2, R5, R7) of 20min after cleaning of the tested area are measured, and then the tested area is provided with skin elasticity indexes R2, R5 and R7 values (the negative pressure is constant at 450mbar in the test process) after the tested area is subjected to the test article by the subjects for keeping the test articles in use for 1 week, 2 weeks, 3 weeks and 4 weeks every day.
Specification of indexes: the closer the skin elasticity indexes R2, R5, R7 are to 1, the better the elasticity of the skin.
R2=Ua/Uf;R5=Ur/Ue;R7=Ur/Uf
Uf — maximum skin stretch;
ue — the amount of stretching of the skin at 0.1 second after constant negative pressure is applied to the skin, the amount of stretching of the elastic portion is located;
ur-after negative pressure is eliminated, the skin can quickly recover to the original state, and the skin is also divided into an elastic part value Ur, namely, after the negative pressure is eliminated for 0.1 second, the recovery value and the viscoelastic part value, or called as a plastic part value, of the skin;
ua-the recovery value of the skin from the elimination of the negative pressure to the next successive test of the skin surface plus the negative pressure.
The results are shown in Table 3
Experimental period | R2 | R5 | R7 |
0 | 0.4287 | 0.4063 | 0.4573 |
1 | 0.6345 | 0.5883 | 0.6032 |
2 | 0.7231 | 0.6632 | 0.7678 |
3 | 0.8502 | 0.8096 | 0.8512 |
4 | 0.9231 | 0.9053 | 0.9131 |
As can be seen from table 3, R2, R5, and R7 increased after the first week using the red ginseng original oxygen-activating eye cream prepared in example 1, wherein the values of R2, R5, and R7 approached 1 at week 4, and the skin elasticity index of the subject was greatly improved, and thus, the red ginseng original oxygen-activating eye cream has the effects of increasing skin elasticity and anti-aging.
Experimental example 3:
the eye cream products produced in the early stage of the department are taken as comparative examples, and the red ginseng vigor activating oxygen eye cream products prepared in the examples 1 to 3 and the comparative examples are compared in clinical experiments. The test conditions were: 50 women aged 35-50, 2 times per day, were applied evenly around the eyes, and the skin was recommended to be cleaned and then used for 30 days. The volunteers who felt improved in moisturizing, lightening fine lines and lightening dark circles after the end of the test were compared to, for example, table 4:
table 4:
test items | Example 1 | Example 2 | Example 3 | Comparative example |
Moisture retention and water retention | 80% | 82% | 88% | 60% |
Thin lines of desalination | 84% | 78% | 90% | 56% |
Fading black eye | 82% | 84% | 88% | 56% |
As can be seen from table 4, compared with the existing products, the red ginseng primordial qi activating oxygen eye cream in the embodiments 1 to 3 of the present invention is successfully qualified in the test items, and the high quality eye cream is realized. Meanwhile, in test items, the effects of moisture retention, fine line fading and dark eye circle fading shown in the examples 1 to 3 of the invention are superior to those of the existing eye cream, and the combined action of the red ginseng and other raw materials is fully exerted. Among them, the best effect is obtained in example 3.
Claims (8)
1. Red ginseng original qi oxygen activating eye cream is characterized in that: the material is prepared from the following raw materials in percentage by weight:
phase A: 31.05-68.43% of water, 4-5% of methyl propylene glycol, 2-5% of glycerol, 0.01-0.05% of hyaluronic acid, 0.01-0.05% of EDTA disodium and 0.1-0.2% of methyl ester; glyceryl polyether-262-5%, PEG/PPG-17/6 copolymer 0.5-3%;
phase B: 2-4% of emulsifier A, 0.5-1% of emulsifier B, 0.5-1% of beeswax, 0.5-1.5% of GMS 30SE, 0.3-1% of 16\18 alcohol, 0.1-0.15% of propyl ester, 0.5-1% of shea butter, 0.5-1% of silicone oil A, 0.5-1% of vitamin E, 3-5% of hydrogenated polydecene, 2-5% of macadamia nut oil, 2-5% of octyldodecanol and 2-5% of silicone oil B;
and C phase: sodium acrylate/sodium acryloyldimethyl taurate copolymer/isohexadecane/polysorbate-801-2%;
phase D: 0.5-2% of red ginseng extract, 0.2-0.5% of carnosine, 1-3% of dipalmitoyl hydroxyproline and 3-6% of water;
phase E: 0.5-2% of glyceryl glucoside, 0.5-2% of chicory tilianin, 0.5-1% of compound anti-allergy agent, 0.05-0.1% of essence and 0.3-0.4% of phenoxyethanol/chlorphenesin.
2. The red ginseng vigor activating oxygen eye cream according to claim 1, wherein: the material is prepared from the following raw materials in percentage by weight:
phase A: 64.01 percent of water, 4 percent of methyl propylene glycol, 2 percent of glycerol, 0.02 percent of hyaluronic acid, 0.02 percent of EDTA disodium and 0.2 percent of methyl ester; glyceryl polyether-263%, PEG/PPG-17/6 copolymer 1%;
phase B: 2.5% of emulsifier A, 0.5% of emulsifier B, 0.8% of beeswax, 1.2% of GMS 30SE, 0.4% of 16\18 alcohol, 0.1% of propyl ester, 0.5% of shea butter, 0.5% of silicone oil A, 0.5% of vitamin E, 3% of hydrogenated polydecene, 2% of macadamia nut oil, 3% of octyldodecanol and 3% of silicone oil B;
and C phase: sodium acrylate/sodium acryloyldimethyl taurate copolymer/isohexadecane/polysorbate-801%;
phase D: 0.6% of red ginseng extract, 0.2% of carnosine, 1% of dipalmitoyl hydroxyproline and 3% of water;
phase E: 0.5 percent of glycerin glucoside, 0.5 percent of chicory tiraparin, 0.5 percent of composite anti-allergy agent, 0.1 percent of essence and 0.35 percent of phenoxyethanol/chlorphenesin.
3. The red ginseng vigor activating oxygen eye cream according to claim 1, wherein: and the silicone oil A in the phase B is polydimethylsiloxane, and the silicone oil B is cyclopenta polydimethylsiloxane/cyclohexasiloxane.
4. The red ginseng vigor activating oxygen eye cream according to claim 1, wherein: beeswax in phase B was beeswax 8044.
5. The red ginseng vigor activating oxygen eye cream according to claim 1, wherein: emulsifier A in phase B is M68 emulsifier, and emulsifier B is A165 emulsifier.
6. The red ginseng vigor activating oxygen eye cream according to claim 1, wherein: the water in phase A and phase D is deionized water.
7. The method for preparing red ginseng vigor activating oxygen eye cream according to any one of claims 1 to 6, comprising the steps of:
step 1: proportioning raw materials of the phase A, the phase B, the phase C, the phase D and the phase E;
step 2: mixing, dispersing and stirring the phase D raw material uniformly to obtain a solution A;
step 2: putting the phase A raw material into a vacuum homogenizing emulsifying pot, starting stirring at the rotating speed of 60rpm, heating to 85-90 ℃, continuously stirring and preserving heat for 5-8min to obtain a solution B;
and step 3: putting the phase B raw material into an oil phase pot, starting stirring at the rotating speed of 40rpm, heating to 80-85 ℃, continuously stirring and preserving heat for 5-8min to completely dissolve the raw material to obtain a solution C;
and 4, step 4: opening the vacuum homogenizing emulsifying pot in the step 2 to vacuum, starting stirring at a rotating speed of 60rpm, pumping the solution C obtained in the step 3 into the vacuum homogenizing emulsifying pot, mixing the solution C with the solution B, opening the vacuum homogenizing emulsifying pot to homogenize at a rotating speed of 2800rpm for 5min, stirring at a rotating speed of 30rpm, keeping the temperature and stirring for 8-10min, and then, starting cooling to obtain a solution D;
and 5: cooling the solution D obtained in the step 4 to 60 ℃, adding the phase C raw material into a vacuum homogenizing emulsifying pot, mixing the phase C raw material with the solution D, starting homogenizing at the rotating speed of 2500rpm for 2min, and continuously stirring and cooling to obtain a solution E;
step 6: cooling the solution E obtained in the step 5 to 45 ℃, then adding the solution A and the E-phase raw material obtained in the step 1, and continuously stirring for 20-30min to obtain a solution F:
and 7: and (4) sampling and detecting the solution F obtained in the step (6), and filtering and discharging after the solution F is qualified.
8. The method for preparing the vigor-activating and oxygen-activating eye cream according to claim 7, wherein the detection in the step 7 comprises appearance detection, viscosity detection, pH value detection, heat resistance detection, cold resistance detection and centrifugation detection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010954426.6A CN112220714A (en) | 2020-09-11 | 2020-09-11 | Red ginseng vigor activating oxygen eye cream and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010954426.6A CN112220714A (en) | 2020-09-11 | 2020-09-11 | Red ginseng vigor activating oxygen eye cream and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112220714A true CN112220714A (en) | 2021-01-15 |
Family
ID=74117064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010954426.6A Pending CN112220714A (en) | 2020-09-11 | 2020-09-11 | Red ginseng vigor activating oxygen eye cream and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112220714A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108969444A (en) * | 2018-09-19 | 2018-12-11 | 陈洁珍 | One kind removing black eye, crease-resistant Firm anti-age corrective eye treatment cream and preparation method thereof |
CN110302113A (en) * | 2019-08-06 | 2019-10-08 | 广州珈纳生物科技有限公司 | One kind is crease-resistant to remove black eye eye cream |
CN111568797A (en) * | 2020-04-29 | 2020-08-25 | 泉后(广州)生物科技研究院有限公司 | Composition for quickly removing fine lines and application thereof |
-
2020
- 2020-09-11 CN CN202010954426.6A patent/CN112220714A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108969444A (en) * | 2018-09-19 | 2018-12-11 | 陈洁珍 | One kind removing black eye, crease-resistant Firm anti-age corrective eye treatment cream and preparation method thereof |
CN110302113A (en) * | 2019-08-06 | 2019-10-08 | 广州珈纳生物科技有限公司 | One kind is crease-resistant to remove black eye eye cream |
CN111568797A (en) * | 2020-04-29 | 2020-08-25 | 泉后(广州)生物科技研究院有限公司 | Composition for quickly removing fine lines and application thereof |
Non-Patent Citations (1)
Title |
---|
广东美啦美化妆品股份有限公司: "美肌颜BIOISIS红参元气套盒-红参元气活氧眼霜", 《国产非特殊用途化妆品备案服务平台》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108670943B (en) | Plant extract composition with moisturizing, whitening and spot-lightening functions | |
CN105147591B (en) | A kind of crease-resistant face cream and preparation method thereof | |
CN111840144B (en) | Moisturizing and repairing composition, skin care product and preparation method thereof | |
CN108969444B (en) | Black eye removing, anti-wrinkle firming and repairing eye cream and preparation method thereof | |
CN111407685A (en) | Anti-aging composition of recombinant fibronectin-human-like collagen and preparation method thereof | |
CN111067840A (en) | Polypeptide whitening and repairing wash-free mask | |
EP3552598A1 (en) | Composition containing crocus sativus extract and preparation method and use thereof | |
CN104042529A (en) | Anti-allergic cosmetic composition and preparation method thereof | |
CN115154375A (en) | Stable cleaning composition with repairing and relieving effects | |
CN110496176A (en) | The Chinese medicine health-care emplastrum and preparation method thereof for treating glaucoma and astigmatism | |
CN117257691A (en) | Composition for reducing neck wrinkles, neck mask patch and preparation method thereof | |
CN111568827A (en) | Moisturizing and makeup removing mousse | |
CN112220714A (en) | Red ginseng vigor activating oxygen eye cream and preparation method thereof | |
CN115364039B (en) | Acne skin repair composition and application thereof | |
CN106511253A (en) | Whitening and moisturizing facial mask cream and preparation method thereof | |
CN110522662A (en) | A kind of ganoderma lucidum face cream and preparation method thereof | |
CN110025558B (en) | Soybean polysaccharide-rich amino acid nano facial cleanser and preparation method thereof | |
CN108078906B (en) | Tea oil hair mask for hair waving and dyeing and preparation method and application thereof | |
CN114306194A (en) | Freckle-removing cosmetic composition containing umbilical cord blood extract, freckle-removing cream and preparation method thereof | |
CN113712894A (en) | Essence emulsion composition with moisturizing and relieving effects and preparation method and application thereof | |
CN109010105B (en) | Multi-effect composition and preparation method and application thereof | |
CN112137947A (en) | Preparation method of special-effect high-moisture-retention emulsion | |
CN108721174A (en) | A kind of anti-aging skin care product and preparation method thereof of addition Fructus Cannabis extract | |
CN115089539B (en) | Skin tightening plant extract composition and preparation method and application thereof | |
CN110538087A (en) | Polypeptide tightening and lifting face cream |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210115 |
|
RJ01 | Rejection of invention patent application after publication |